Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial
Peripheral blood-derived indicators are prognostic markers for HR-positive, HER2-negative metastatic breast cancer. Elevated PLR during treatment indicates poor response to CDK4/6 inhibitors.
Authors
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Yan Hu (ORCID: https://orcid.org/0000-0003-0451-4642)
- Yiran Zhou (ORCID: https://orcid.org/0000-0002-1965-8414)
- Xianghui Duan
- Xinxin Tan
- Liang Cui (ORCID: https://orcid.org/0000-0002-4785-9678)
- Jiayu Wang (ORCID: https://orcid.org/0000-0003-1967-389X)
- Jing Bai (ORCID: https://orcid.org/0009-0003-9650-3023)
- Ruigang Cai
- Bo Lan (ORCID: https://orcid.org/0000-0002-2962-439X)
- Yan Wang (ORCID: https://orcid.org/0000-0001-6957-7690)
- Qiao Li (ORCID: https://orcid.org/0000-0002-7472-5333)
- Pin Zhang (ORCID: https://orcid.org/0000-0002-7141-9541)
- Jiani Wang (ORCID: https://orcid.org/0000-0002-0869-3468)
- Ying Fan (ORCID: https://orcid.org/0000-0003-3419-9399)
- Hangcheng Xu
- Fan Yang (ORCID: https://orcid.org/0000-0003-4068-0808)
- Qiang Sa
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Beijing Biocytogen (China) (CN)
Publication Details
- Journal
- The Breast
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1016/j.breast.2025.104598
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04